Literature DB >> 7482738

The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation.

B J Periera1, T L Wright, C H Schmid, A S Levey.   

Abstract

Controversy exists regarding the impact of pretransplantation HCV infection on the outcome of renal transplantation. We compared the prevalence of posttransplantation liver disease and graft and patient survival among kidney transplant recipients with and without anti-HCV at the time of transplantation. Pretransplantation sera from 103 randomly selected recipients of kidneys from anti-HCV-negative donors were tested for anti-HCV using a second generation ELISA. Twenty-three (22%) were positive for anti-HCV and 80 (78%) were negative. Anti-HCV-positive recipients had a longer time on dialysis (P = 0.003) and had a higher number of previous transplants (P = 0.01). Further, 61% of anti-HCV-positive patients had a history of liver disease compared with 13% of anti-HCV-negative patients (P < 0.001). HCV RNA was detected in the pretransplantation serum in 61% of anti-HCV positive recipients compared with 5% of anti-HCV-negative recipients (P < 0.001). Clinical follow-up on both anti-HCV-positive and -negative patients was obtained until December, 1993. Median posttransplantation follow-up among recipients with anti-HCV prior to transplantation (45 months) was shorter (P = 0.05) than that for recipients without anti-HCV (66 months). For recipients with anti-HCV prior to transplantation, the relative risk of posttransplantation liver disease was 5.0 (95% confidence intervals of 2.4 to 10.5); the relative risk of graft loss was 1.3 (95% confidence intervals of 0.6 to 2.6); the relative risk of death was 3.3 (95% confidence intervals of 1.4 to 7.9), and the relative risk of death due to sepsis was 9.9 (95% confidence intervals of 2.6 to 38.3). The results of this study demonstrate that pretransplantation HCV infection is associated with an increased risk of liver disease and death after renal transplantation. These results raise the question of whether anti-HCV-positive patients on dialysis should be offered renal transplantation as opposed to continuing dialysis.

Entities:  

Mesh:

Year:  1995        PMID: 7482738

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  22 in total

Review 1.  Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation.

Authors:  Greg Knoll; Sandra Cockfield; Tom Blydt-Hansen; Dana Baran; Bryce Kiberd; David Landsberg; David Rush; Edward Cole
Journal:  CMAJ       Date:  2005-11-08       Impact factor: 8.262

2.  Impact of Willingness to Accept Hepatitis C Seropositive Kidneys Among Hepatitis C RNA-Positive Waitlisted Patients.

Authors:  Junichiro Sageshima; Christoph Troppmann; John P McVicar; Chandrasekar Santhanakrishnan; Angelo M de Mattos; Richard V Perez
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

Review 3.  Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation.

Authors:  Chrysoula Pipili; Evangelos Cholongitas
Journal:  World J Hepatol       Date:  2014-05-27

4.  Incidence of CMV-HCV coinfection in renal transplant recipient.

Authors:  Avirup Chakraborty; Krishna Patil; Sanjay Dasgupta; Abhijit Tarafdar; Sekhar Chakrabarti; Nilanjan Chakraborty
Journal:  BMJ Case Rep       Date:  2012-04-02

Review 5.  Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation.

Authors:  Lucy Somerville; Karen Doucette
Journal:  Curr Infect Dis Rep       Date:  2018-05-22       Impact factor: 3.725

Review 6.  Management of hepatitis C in patients with chronic kidney disease.

Authors:  Roberto J Carvalho-Filho; Ana Cristina C A Feldner; Antonio Eduardo B Silva; Maria Lucia G Ferraz
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

7.  Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients.

Authors:  Abdulrahman A Aljumah; Mohamed A Saeed; Ahmed I Al Flaiw; Ibrahim H Al Traif; Abduljaleel M Al Alwan; Salem H Al Qurashi; Ghormallah A Al Ghamdi; Fayez F Al Hejaili; Mohammed A Al Balwi; Abdulla A Al Sayyari
Journal:  World J Gastroenterol       Date:  2012-01-07       Impact factor: 5.742

8.  HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin.

Authors:  Wyel Hakim; Shehzad Sheikh; Irteza Inayat; Cary Caldwell; Douglas Smith; Marc Lorber; Amy Friedman; Dhanpat Jain; Margaret Bia; Richard Formica; Wajahat Mehal
Journal:  J Clin Gastroenterol       Date:  2009 May-Jun       Impact factor: 3.062

Review 9.  Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon.

Authors:  Sara Belga; Karen Elizabeth Doucette
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

10.  Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States.

Authors:  Nae-Yun Heo; Ajitha Mannalithara; Donghee Kim; Prowpanga Udompap; Jane C Tan; W Ray Kim
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.